Mumbai: The civic-run King Edward Memorial (KEM) Hospital in Mumbai on Wednesday began phase II and III trials of the Oxford Covishield vaccine for COVID-19, an official said.
The hospital, located in Parel area, on Tuesday got the approval of the Maharashtra ethics committee for conducting the vaccine trials.
KEM Hospital Dean Dr Hemant Deshmukh told PTI that the hospital has started screening volunteers for the trials.
The medical facility will be conducting the trials on 100 volunteers, he said.
The city-based B Y L Nair Hospital, another facility run by the Brihanmumbai Municipal Corporation, has also received approval for conducting trials of the vaccine.
Both the KEM and Nair hospitals will be conducting the trials collectively on over 200 volunteers, sources said.
As part of the trials, volunteers who are found negative for coronavirus in both RT-PCR and antigen tests will be given the vaccine, they said.
Trials of the Oxford vaccine candidate are being conducted in Pune also.
The Pune-based Serum Institute of India (SII) has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, being developed by the University of Oxford, UK.
Subscribe to our channels on YouTube & Telegram
Why news media is in crisis & How you can fix it
You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.
You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.
We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And have just turned three.
At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.
This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.
If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrint’s future.